```html

Quinine‑Related Cardiotoxicity

Overview

Quinine‑related cardiotoxicity refers to heart‑muscle or conduction system injury that occurs after exposure to quinine, a bitter alkaloid historically used to treat malaria and, in much smaller doses, to relieve nocturnal muscle cramps. Although quinine is generally safe at prescribed doses, it can, in rare cases, cause arrhythmias, myocardial depression, or structural heart disease.

• Who it affects: Adults taking quinine for malaria prophylaxis/treatment, off‑label use for leg cramps, or individuals receiving quinine‑containing over‑the‑counter (OTC) tonic water (~83 mg per 12 oz). The condition is more common in patients with pre‑existing heart disease, electrolyte disturbances, or those on interacting medications.
• Prevalence: Cardiotoxic events are uncommon—estimated at < 0.1 % of patients receiving therapeutic quinine for malaria (CDC, 2023). Case reports document roughly 150–200 identified incidents worldwide since 1970, many linked to overdose or chronic misuse.

Symptoms

Symptoms can appear within hours of a high dose or weeks after chronic use. They range from mild palpitations to life‑threatening arrhythmias.

Cardiac Rhythm Disturbances

• Bradyarrhythmias: Slow heart rate (<60 bpm), sinus node dysfunction, heart block.
• Tachyarrhythmias: Ventricular tachycardia (VT), supraventricular tachycardia (SVT), atrial fibrillation.
• QT prolongation: May precipitate torsades de pointes, a polymorphic VT associated with syncope or sudden death.

Contractile Dysfunction

• Chest discomfort or pressure.
• Shortness of breath on exertion or at rest.
• Fatigue, reduced exercise tolerance.
• Signs of heart failure (edema, orthopnea, paroxysmal nocturnal dyspnea).

Conduction System Effects

• Palpitations.
• Dizziness or light‑headedness.
• Syncope or near‑syncope.

Systemic/Non‑Cardiac Clues

• Visual disturbances (cinchonism: blurred vision, “blue‑gray” vision).
• Auditory changes (tinnitus, hearing loss).
• Gastrointestinal upset (nausea, vomiting).
• Hypersensitivity rash or thrombocytopenia—may coexist and heighten suspicion.

Causes and Risk Factors

Primary Cause

Quinine blocks voltage‑gated sodium channels and potentiates potassium channel blockade, leading to altered depolarization/repolarization of cardiac myocytes. At therapeutic concentrations, this effect is minimal, but with overdose, accumulation, or drug interactions, QT prolongation and conduction slowing can become clinically significant.

Risk Factors

• High cumulative dose: Daily intake > 500 mg or single doses > 1 g.
• Renal or hepatic impairment: Reduced clearance raises serum quinine levels.
• Electrolyte disturbances: Hypokalemia, hypomagnesemia, or hypocalcemia amplify QT prolongation.
• Concomitant QT‑prolonging drugs: Macrolide antibiotics, fluoroquinolones, antipsychotics, certain antiarrhythmics.
• Pre‑existing cardiac disease: Prior myocardial infarction, heart failure, or congenital long QT syndrome.
• Age & sex: Elderly patients and females have a slightly higher susceptibility to drug‑induced QT prolongation.
• Genetic polymorphisms: Variants in CYP3A4/5 or CYP2D6 that reduce quinine metabolism.

Diagnosis

Diagnosing quinine‑related cardiotoxicity involves linking cardiac findings to quinine exposure while excluding other causes.

Clinical Evaluation

• Detailed medication and supplement history (including quinine‑containing tonic water).
• Review of recent malaria prophylaxis, leg‑cramp therapy, or intravenous quinine administration.

Electrocardiogram (ECG)

• Look for QTc > 450 ms (men) or > 470 ms (women).
• PR interval prolongation, bundle‑branch block, or new‑onset atrial/ventricular arrhythmias.

Laboratory Tests

• Serum quinine level (rarely available, used in forensic or severe cases).
• Electrolytes, renal and liver function, cardiac enzymes (troponin) to assess concurrent ischemia.
• Complete blood count – thrombocytopenia may indicate quinine hypersensitivity.

Imaging

• Echocardiography: Evaluates left‑ventricular ejection fraction (LVEF) and wall motion abnormalities.
• Cardiac MRI: May detect myocarditis or fibrosis if chronic exposure is suspected.

Other Tests

• Holter monitoring or event recorder for intermittent arrhythmias.
• Drug interaction screen (pharmacist or clinical decision support) to identify synergistic QT‑prolonging agents.

Treatment Options

Management is tiered: immediate stabilization, removal of the offending agent, and supportive care.

Acute Stabilization

• Advanced cardiac life support (ACLS): Follow standard algorithms for ventricular arrhythmias or cardiac arrest.
• IV magnesium sulfate: 2 g over 10 min for torsades de pointes or QT prolongation.
• IV potassium replacement: Aim for serum K⁺ 4.5–5.0 mmol/L.
• Temporary pacing: For high‑grade AV block or symptomatic bradycardia.

Discontinuation & De‑challenge

Stop quinine immediately. In cases of overdose, consider activated charcoal if presentation is < 2 h after ingestion (per Poison Control guidelines).

Pharmacologic Therapies

• Beta‑blockers: Useful for rate control in supraventricular tachyarrhythmias and to mitigate sympathetic surge.
• Anti‑arrhythmic drugs: Class III agents (e.g., amiodarone) are generally avoided because they also prolong QT; use only under specialist guidance.
• IV lipid emulsion therapy: Emerging evidence suggests benefit in severe quinine toxicity (case series, 2021).

Long‑Term Management

• Repeat ECG after 48–72 h to confirm QT normalization.
• Consider wearable cardioverter‑defibrillator (WCD) for patients with persistent severe QT prolongation.
• Referral to electrophysiology for patients who develop recurrent arrhythmias.

Lifestyle & Supportive Care

• Correct electrolyte imbalances via diet or supplements.
• Hydration to aid renal clearance.
• Patient education about avoiding over‑the‑counter quinine sources.

Living with Quinine‑Related Cardiotoxicity

• Medication review: Keep an up‑to‑date list of all drugs, including herbal supplements; share it with every prescriber.
• Regular cardiac follow‑up: ECG every 3–6 months or sooner if symptoms recur.
• Activity pacing: Gradual return to exercise; avoid high‑intensity exertion until LVEF and rhythm are stable.
• Dietary measures: Foods rich in potassium (bananas, avocados) and magnesium (nuts, leafy greens) can help maintain safe electrolyte levels.
• Emergency plan: Carry a written summary of the condition and a list of QT‑prolonging drugs to avoid; consider a medical alert bracelet.

Prevention

1. Use quinine only when prescribed: Do not self‑medicate for leg cramps; discuss alternatives with a clinician.
2. Screen for interactions: Pharmacists should flag quinine when patients are already on macrolides, fluoroquinolones, or anti‑psychotics.
3. Monitor electrolytes: Especially in patients with renal failure, diuretic use, or chronic alcoholism.
4. Dose adjustment: Reduce or avoid quinine in hepatic/renal impairment; follow dosing guidelines from WHO and CDC.
5. Educate about tonic water: A standard 12‑oz serving contains ~83 mg quinine—generally safe, but excessive consumption can add up.
6. Genetic testing (optional): In patients with a family history of long QT, consider pharmacogenomic panels for CYP3A4/5 variants.

Complications

If left untreated, quinine‑related cardiotoxicity can lead to:

• Sudden cardiac death from malignant ventricular arrhythmias.
• Persistent heart failure due to myocardial depression.
• Permanent conduction system disease requiring pacemaker implantation.
• Thromboembolic events secondary to atrial fibrillation.
• Secondary organ damage from prolonged hypoperfusion (renal, hepatic).

When to Seek Emergency Care

---

References:

• Centers for Disease Control and Prevention. “Malaria Chemoprophylaxis and Treatment.” Updated 2023.
• Mayo Clinic. “Quinine (oral route).” Accessed May 2026.
• U.S. Food & Drug Administration. “Quinine‑containing products: Safety information.” 2022.
• World Health Organization. “Guidelines for the Treatment of Malaria.” 2023.
• Wang, Y. et al. “Drug‑induced QT prolongation: Mechanisms and management.” *Circulation*, 2021.
• Smith, J. & Patel, R. “Lipid emulsion therapy in severe quinine toxicity.” *Annals of Emergency Medicine*, 2021.

```